Characteristics | Categories | Total | 2002-2005 | 2006-2007 |
---|---|---|---|---|
Patients | 4317 | 2687 | 1630 | |
Continent of origin, no (%) | Western Europe | 2404 (56) | 1608 (60) | 796 (49) |
Eastern Europe & Central Asia | 919 (21) | 424 (16) | 495 (30) | |
Sub-Saharan Africa | 472 (11) | 323 (12) | 149 (9) | |
Other | 354 (8) | 190 (7) | 164 (10) | |
Unknown | 168 (4) | 142 (5) | 26 (2) | |
Gender, no. (%) | Male | 3411 (79) | 2080 (77) | 1331 (82) |
Risk group, no. (%) | MSM | 2084 (48) | 1230 (46) | 854 (52) |
Hetero | 1501 (35) | 1004 (37) | 497 (30) | |
Injecting drug use | 355 (8) | 208 (8) | 147 (9) | |
Unknown | 377 (9) | 245 (9) | 132 (8) | |
Subtype, no. (%) | B | 2855 (66) | 1777 (66) | 1078 (66) |
non-B | 1381 (32) | 849 (32) | 532 (33) | |
Unknown | 81 (2) | 61 (2) | 20 (1) | |
Duration of infection, no (%) | <1 year | 1236 (29) | 724 (27) | 512 (31) |
1-2 years | 144 (3) | 77 (3) | 67 (4) | |
Unknown | 2937 (68) | 1886 (70) | 1051 (64) | |
Plasma HIV-RNA, median (IQR), log copies/ml | 4.9 (4.3-5.3) | 4.9 (4.3-5.3) | 4.8 (4.2-5.4) | |
CD4 cell count, median (IQR), cells/mm3 | 352 (180–540) | 343 (163–533) | 370 (210–548) | |
Age, median years (IQR) | 35 (29–42) | 35 (29–42) | 35 (29–42) |